Astrazeneca Plc Adr Stock Buy Hold or Sell Recommendation
| AZN Stock | USD 68.36 0.17 0.25% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding AstraZeneca PLC ADR is 'Strong Hold'. Macroaxis provides AstraZeneca PLC buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AZN positions. The advice algorithm takes into account all of AstraZeneca PLC's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting AstraZeneca PLC's buy or sell advice are summarized below:
Real Value 59.91 | Target Price 83.71 | Hype Value 68.36 | Market Value 68.36 | Naive Value 69.48 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell AstraZeneca PLC ADR given historical horizon and risk tolerance towards AstraZeneca PLC. When Macroaxis issues a 'buy' or 'sell' recommendation for AstraZeneca PLC ADR, the advice is generated through an automated system that utilizes algorithms and statistical models.
AstraZeneca |
Execute AstraZeneca PLC Buy or Sell Advice
The AstraZeneca recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on AstraZeneca PLC ADR. Macroaxis does not own or have any residual interests in AstraZeneca PLC ADR or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute AstraZeneca PLC's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
AstraZeneca PLC Trading Alerts and Improvement Suggestions
| The company has 28.62 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC ADR has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity. | |
| On 25th of March 2024 AstraZeneca PLC paid $ 0.985 per share dividend to its current shareholders | |
| Latest headline from aol.com: Kids need to breathe just like adults do 35 price caps dont apply to asthma meds young children need, doctors say |
AstraZeneca PLC Returns Distribution Density
The distribution of AstraZeneca PLC's historical returns is an attempt to chart the uncertainty of AstraZeneca PLC's future price movements. The chart of the probability distribution of AstraZeneca PLC daily returns describes the distribution of returns around its average expected value. We use AstraZeneca PLC ADR price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of AstraZeneca PLC returns is essential to provide solid investment advice for AstraZeneca PLC.
| Mean Return | 0.05 | Value At Risk | -1.81 | Potential Upside | 2.28 | Standard Deviation | 1.22 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of AstraZeneca PLC historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
AstraZeneca Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AstraZeneca PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AstraZeneca PLC ADR backward and forwards among themselves. AstraZeneca PLC's institutional investor refers to the entity that pools money to purchase AstraZeneca PLC's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Atlantic Trust Group, Llc | 2023-12-31 | 10.4 M | Franklin Resources Inc | 2023-12-31 | 9.8 M | Fisher Asset Management, Llc | 2023-12-31 | 9.4 M | Capital World Investors | 2023-12-31 | 9.3 M | Putnam Investments Llc | 2023-12-31 | 7.7 M | Blackrock Inc | 2023-12-31 | 6.5 M | Ameriprise Financial Inc | 2023-12-31 | 4.4 M | Dimensional Fund Advisors, Inc. | 2023-12-31 | 4 M | Farallon Capital Management, L.l.c. | 2023-12-31 | 3.8 M | T. Rowe Price Associates, Inc. | 2023-12-31 | 52.3 M | Wellington Management Company Llp | 2023-12-31 | 49.4 M |
AstraZeneca PLC Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (316M) | (621M) | 1.6B | 3.9B | (669M) | (635.6M) | |
| Change In Cash | 552M | 2.3B | (1.5B) | (55M) | (346M) | (363.3M) | |
| Free Cash Flow | 509M | 2.2B | 3.8B | 7.2B | 6.6B | 6.9B | |
| Depreciation | 3.8B | 3.1B | 6.5B | 5.5B | 4.9B | 5.2B | |
| Other Non Cash Items | (2.0B) | (2.6B) | (2.3B) | (1.9B) | (1.8B) | (1.9B) | |
| Capital Expenditures | 2.5B | 2.6B | 2.2B | 2.6B | 3.8B | 1.9B | |
| Net Income | 1.5B | 3.9B | (265M) | 2.5B | 6.9B | 4.4B | |
| End Period Cash Flow | 5.2B | 7.5B | 6.0B | 6.0B | 5.6B | 4.1B | |
| Dividends Paid | 3.6B | 3.6B | 3.9B | 4.4B | (4.5B) | (4.3B) | |
| Investments | 125M | (285M) | 605M | (3.0B) | (3.2B) | (3.1B) | |
| Net Borrowings | (1.7B) | 1.4B | 7.7B | (1.4B) | (1.7B) | (1.6B) | |
| Change To Netincome | (816M) | (1.7B) | (272M) | (2.5B) | (2.2B) | (2.1B) |
AstraZeneca PLC Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to AstraZeneca PLC or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that AstraZeneca PLC's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a AstraZeneca stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.01 | |
β | Beta against NYSE Composite | 0.61 | |
σ | Overall volatility | 1.22 | |
Ir | Information ratio | -0.01 |
AstraZeneca PLC Volatility Alert
AstraZeneca PLC ADR has relatively low volatility with skewness of -0.3 and kurtosis of 2.71. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure AstraZeneca PLC's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact AstraZeneca PLC's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.AstraZeneca PLC Implied Volatility
AstraZeneca PLC's implied volatility exposes the market's sentiment of AstraZeneca PLC ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if AstraZeneca PLC's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that AstraZeneca PLC stock will not fluctuate a lot when AstraZeneca PLC's options are near their expiration.
AstraZeneca PLC Fundamentals Vs Peers
Comparing AstraZeneca PLC's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze AstraZeneca PLC's direct or indirect competition across all of the common fundamentals between AstraZeneca PLC and the related equities. This way, we can detect undervalued stocks with similar characteristics as AstraZeneca PLC or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of AstraZeneca PLC's fundamental indicators could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare AstraZeneca PLC to competition |
| Fundamentals | AstraZeneca PLC | Peer Average |
| Return On Equity | 0.16 | -0.31 |
| Return On Asset | 0.066 | -0.14 |
| Profit Margin | 0.13 % | (1.27) % |
| Operating Margin | 0.17 % | (5.51) % |
| Current Valuation | 130.04 B | 16.62 B |
| Shares Outstanding | 3.1 B | 571.82 M |
| Shares Owned By Institutions | 16.80 % | 39.21 % |
| Number Of Shares Shorted | 7.66 M | 4.71 M |
| Price To Earning | 103.39 X | 28.72 X |
| Price To Book | 5.46 X | 9.51 X |
| Price To Sales | 4.67 X | 11.42 X |
| Revenue | 45.81 B | 9.43 B |
| Gross Profit | 35.73 B | 27.38 B |
| EBITDA | 13.91 B | 3.9 B |
| Net Income | 6.9 B | 570.98 M |
| Cash And Equivalents | 4.52 B | 2.7 B |
| Cash Per Share | 1.46 X | 5.01 X |
| Total Debt | 28.62 B | 5.32 B |
| Debt To Equity | 0.89 % | 48.70 % |
| Current Ratio | 0.81 X | 2.16 X |
| Book Value Per Share | 25.25 X | 1.93 K |
| Cash Flow From Operations | 10.35 B | 971.22 M |
| Short Ratio | 1.61 X | 4.00 X |
| Earnings Per Share | 1.91 X | 3.12 X |
| Price To Earnings To Growth | 0.89 X | 4.89 X |
| Target Price | 81.81 | |
| Number Of Employees | 89.9 K | 18.84 K |
| Beta | 0.19 | -0.15 |
| Market Capitalization | 211.61 B | 19.03 B |
| Total Asset | 101.12 B | 29.47 B |
| Retained Earnings | 1.5 B | 9.33 B |
| Working Capital | (5.49 B) | 1.48 B |
| Current Asset | 16.01 B | 9.34 B |
AstraZeneca PLC Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as AstraZeneca . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About AstraZeneca PLC Buy or Sell Advice
When is the right time to buy or sell AstraZeneca PLC ADR? Buying financial instruments such as AstraZeneca Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 30.8B | 29.2B | 28.6B | 30.1B | Total Assets | 105.4B | 96.5B | 101.1B | 106.2B |
Use Investing Ideas to Build Portfolios
In addition to having AstraZeneca PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Chemicals Makers Thematic Idea Now
Chemicals Makers
Companies developing chemicals for crops, soil as well as human, and animals. The Chemicals Makers theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Makers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out AstraZeneca PLC Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.059 | Dividend Share 2.9 | Earnings Share 1.91 | Revenue Per Share 2.4547 | Quarterly Revenue Growth 0.073 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.